Taigen Biopharmaceuticals Holdings Ltd - Asset Resilience Ratio

Latest as of December 2025: 75.53%

Taigen Biopharmaceuticals Holdings Ltd (4157) has an Asset Resilience Ratio of 75.53% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Taigen Biopharmaceuticals Holdings Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets

NT$881.66 Million

≈ $27.78 Million USD Cash + Short-term Investments

Total Assets

NT$1.17 Billion

≈ $36.77 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Taigen Biopharmaceuticals Holdings Ltd's Asset Resilience Ratio has changed over time. See Taigen Biopharmaceuticals Holdings Ltd (4157) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Taigen Biopharmaceuticals Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Taigen Biopharmaceuticals Holdings Ltd stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$881.66 Million	75.53%
Total Liquid Assets	NT$881.66 Million	75.53%

Asset Resilience Insights

Very High Liquidity: Taigen Biopharmaceuticals Holdings Ltd maintains exceptional liquid asset reserves at 75.53% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Taigen Biopharmaceuticals Holdings Ltd Industry Peers by Asset Resilience Ratio

Compare Taigen Biopharmaceuticals Holdings Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHG:603392	Biotechnology	11.64%
Amicus Therapeutics Inc NASDAQ:FOLD	Biotechnology	8.37%
China Resources Boya Bio pharmaceutical Group Co Ltd SHE:300294	Biotechnology	23.15%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	82.25%
Jiangsu Sihuan Bioengineering Co Ltd SHE:000518	Biotechnology	0.03%
Yantai Zhenghai Bio-Tech Co Ltd SHE:300653	Biotechnology	56.48%
Jiangsu GDK Biotechnology Co Ltd SHG:688670	Biotechnology	9.82%

Annual Asset Resilience Ratio for Taigen Biopharmaceuticals Holdings Ltd (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Taigen Biopharmaceuticals Holdings Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	75.53%	NT$881.66 Million ≈ $27.78 Million	NT$1.17 Billion ≈ $36.77 Million	-5.00pp
2024-12-31	80.53%	NT$945.68 Million ≈ $29.79 Million	NT$1.17 Billion ≈ $37.00 Million	+26.60pp
2023-12-31	53.94%	NT$663.34 Million ≈ $20.90 Million	NT$1.23 Billion ≈ $38.75 Million	-8.76pp
2022-12-31	62.69%	NT$656.39 Million ≈ $20.68 Million	NT$1.05 Billion ≈ $32.99 Million	+22.52pp
2021-12-31	40.17%	NT$559.46 Million ≈ $17.63 Million	NT$1.39 Billion ≈ $43.88 Million	-8.34pp
2020-12-31	48.51%	NT$269.92 Million ≈ $8.50 Million	NT$556.45 Million ≈ $17.53 Million	-6.07pp
2019-12-31	54.57%	NT$516.33 Million ≈ $16.27 Million	NT$946.11 Million ≈ $29.81 Million	+1.17pp
2018-12-31	53.40%	NT$634.27 Million ≈ $19.98 Million	NT$1.19 Billion ≈ $37.42 Million	-3.22pp
2017-12-31	56.62%	NT$861.84 Million ≈ $27.15 Million	NT$1.52 Billion ≈ $47.96 Million	-8.75pp
2016-12-31	65.37%	NT$538.32 Million ≈ $16.96 Million	NT$823.45 Million ≈ $25.94 Million	+2.70pp
2015-12-31	62.67%	NT$391.97 Million ≈ $12.35 Million	NT$625.46 Million ≈ $19.71 Million	-17.61pp
2014-12-31	80.28%	NT$881.62 Million ≈ $27.78 Million	NT$1.10 Billion ≈ $34.60 Million	+65.56pp
2013-12-31	14.72%	NT$71.61 Million ≈ $2.26 Million	NT$486.49 Million ≈ $15.33 Million	+4.87pp
2012-12-31	9.85%	NT$72.31 Million ≈ $2.28 Million	NT$733.95 Million ≈ $23.12 Million	--

pp = percentage points

About Taigen Biopharmaceuticals Holdings Ltd

TWO:4157 Taiwan Biotechnology

Market Cap

$192.20 Million

NT$6.10 Billion TWD

Market Cap Rank

#16764 Global

#846 in Taiwan

Share Price

NT$8.57

Change (1 day)

-1.95%

52-Week Range

NT$7.52 - NT$15.60

All Time High

NT$37.39